Printer Friendly

Campany Licenses Japanese iPSC Technology.

CAMBRIDGE, Mass., May 9, 2018 -- Platelet BioGenesis, a producer of functional human platelets (PLTs+) from stem cells, has licensed patents related to induced pluripotent stem cells (iPSC) from iPS Academia Japan's patent portfolio.

This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale.

iPS Academia's iPS cell patent portfolio primarily issues from the work of Shinya Yamanaka at the Center for iPS Cell Research and Application at Kyoto University.

The license gives Platelet access to an important processing step needed to produce platelets using its technology. The company has secured control of all the underlying technology needed to produce donor-independent platelets for transfusion.

Other licensees of iPS Academia Japan's technologies include Pfizer, Roche, Sanofi, Bayer, and Boehringer Ingelheim.

iPS cells are derived from somatic cells such as skin or blood cells and have been reprogrammed back into an embryonic-like pluripotent state.

This enables the iPS cells to develop into almost any type of human cells.

At Platelet BioGenesis, the iPS cells are differentiated into megakaryocytes, the cells in the bone marrow that produce platelets, which are crucial for normal blood clotting and the transport of various factors throughout the body.

iPS Academia Japan is the entity established to commercialize the intellectual property of Kyoto University and other prominent universities and research institutions. The iPS cell patent portfolio primarily issues from the work of Professor Shinya Yamanaka at the Center for iPS Cell Research and Application at Kyoto University.

Platelet BioGenesis is a venture-backed, development stage biotech company creating designer platelets (PLTs+) as a new class of therapeutics.

Contact: http://www.plateletbiogenesis.com

Contact: http://www.ips-cell.net

COPYRIGHT 2018 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technology Licensing
Publication:Stem Cell Research News
Geographic Code:9JAPA
Date:May 21, 2018
Words:275
Previous Article:Collaboration To Develop Cardiovascular, Catheter-based Therapies.
Next Article:Stem Cell Technology Fgr Bjood Vessel Regeneration Is Licensed.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |